Results 111 to 120 of about 19,125 (215)

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug

open access: yesArthritis Care &Research, Volume 78, Issue 9, Page 1149-1158, September 2026.
Objective We assessed the effectiveness of PrismRA to improve clinical outcomes among patients with rheumatoid arthritis (RA) initiating treatment with a biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD). Methods PrismRA incorporated 19 gene expression features and four clinical features to assess a patient's likelihood of
Fenglong Xie   +3 more
wiley   +1 more source

Pharmacokinetics and Tissue Distribution in Rats After Oral Administration of Tibetan Medicine Wuwei Leze Powder

open access: yesChemistry &Biodiversity, Volume 23, Issue 9, September 2026.
Wuwei Leze Powder (WLP), a classic Tibetan medicine for rheumatoid arthritis, is orally administered and undergoes extensive absorption and metabolism in rats. A total of 56 plasma constituents, including 21 prototypes and 35 metabolites, are identified.
Ping Wang   +7 more
wiley   +1 more source

Clerodendrum japonicum Extract Suppresses the Pathogenicity of Rheumatoid Arthritis Fibroblast‐Like Synoviocytes by Inhibiting METTL3‐Mediated ICAM2 mRNA Methylation

open access: yesCell Biochemistry and Function, Volume 44, Issue 9, September 2026.
ABSTRACT Clerodendrum japonicum (Thunb.) Sweet (Clerodendrum japonicum) is a traditional medicinal plant with reported anti‐inflammatory use, but its anti‐rheumatoid arthritis (RA) activity and molecular basis remain insufficiently characterized. Activated fibroblast‐like synoviocytes (FLSs) contribute to persistent inflammation and joint destruction ...
Ying Huang   +7 more
wiley   +1 more source

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 684-691, September 2026.
Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu   +4 more
wiley   +1 more source

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS

open access: yesНаучно-практическая ревматология, 2016
Despite major advances in the management of rheumatoid arthritis (RA), whicare associated with the development of new methods for its early diagnosis, the clinical introduction of a wide range of innovative medications and particularly the improvement of
E. L. Nasonov
doaj  

Autoimmunity: Molecular Mechanisms, Biomarkers, and Therapeutic Opportunities

open access: yesMedComm, Volume 7, Issue 9, September 2026.
Major types of immunometabolism, epigenetics, posttranscriptional regulation, and functional reprogramming involved in autoimmune diseases. The roles of immunometabolism, epigenetics, posttranscriptional regulation, and functional reprogramming in autoimmune diseases have been a major research focus in recent years.
Jialong Kuang   +10 more
wiley   +1 more source

Tissue‐Resident Macrophage in Inflammation and Cancer

open access: yesMedComm, Volume 7, Issue 9, September 2026.
Opposing macrophage functions in inflammation and cancer converge on shared mechanistic nodes, informing cross‐disease therapeutic strategies. ABSTRACT Tissue‐resident macrophages (TRMs) are long‐lived immune cells strategically distributed across organs, where their functional plasticity enables both homeostatic maintenance and pathological ...
Siyuan Huang   +13 more
wiley   +1 more source

Impact of Withdrawal of Extended‐Release Morphine 5 mg on Hospital Analgesic Utilization

open access: yes
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Mille Vraa Gamborg Eisenhardt   +4 more
wiley   +1 more source

Trends in Medicines Discontinuation and Implications for Access in Brazil (2014–2024)

open access: yesPharmacoepidemiology and Drug Safety, Volume 35, Issue 9, September 2026.
ABSTRACT Purpose The World Health Organization (WHO) began recognizing drug shortages as a global issue in 2014, impacting health systems and patient care. Shortages arise from supply chain disruptions, production issues, and mismatches between supply and demand, aggravated by insufficient mechanisms for forecasting and communication. Methods The study
Raphaella Oliveira Martins de Lima   +6 more
wiley   +1 more source

Pediatric Use of Off‐Label Medicines and Nonevidence‐Based Supplements for COVID‐19: Findings From the 2015 Pelotas Birth Cohort Study (Brazil)

open access: yesPharmacoepidemiology and Drug Safety, Volume 35, Issue 9, September 2026.
ABSTRACT Purpose Pediatric off‐label medicine use increased during the COVID‐19 pandemic, exposing children to nonevidence‐based treatments. We described the use of nonevidence‐based COVID‐19 medicines and supplements among children from the 2015 Pelotas Birth Cohort, according to sociodemographic and health‐related characteristics.
Andréa Dâmaso Bertoldi   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy